Methods of treatment using conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
What is described is a method of treatment of a patient with a tumor, comprising administering a cell responsive to a peptide comprising a tumor epitope, wherein the tumor epitope comprises an amino acid substitution in a tumor antigen. The tumor antigen is preferably selected from the group consisting of NYESO-I157-165, NYESO-II157-170, or MART-126-35, preferably SEQ ID NOS: 1-351, 361-376, and 392-401.
A A A A A A C
A61K A61K A61K A61K A61K A61K C07K
additional inventional inventional inventional additional additional inventional
Cassian Yongqing C. Siddiq
Yee Li Abdul-Alim